Clinical trial
GLS-5700 in Dengue Virus-Naïve Adults
NCT02809443 · GeneOne Life Science, Inc., Industry · Completed
Key facts
| NCT number | NCT02809443 |
|---|---|
| Title | GLS-5700 in Dengue Virus-Naïve Adults |
| Official title | Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults |
| Lead sponsor | GeneOne Life Science, Inc., Industry |
| Collaborators | Inovio Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | GLS-5700 |
| Enrollment | 40 |
| Start date | Jul 1, 2016 |
| Primary completion | Nov 1, 2017 |
| Completion | Dec 1, 2017 |
| First posted | Jun 22, 2016 |
| Last update posted | Dec 24, 2024 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: